Study Confirms The Value of MTWA Test As A Predictor of Life-Threatening Cardiac Events

Results published in an international cardiology journal show Microvolt T-Wave Alternans to be a strong, independent risk factor for major arrhythmic events

 

July 26, 2012

July 26, 2012 — Cambridge Heart Inc., a developer of non-invasive diagnostic tests for cardiac disease, announced that results of a prospective, 155-patient trial reinforces the value of the Microvolt T-Wave Alternans (MTWA) test as a predictor of life-threatening heart rhythms and sudden cardiac death (SCD). The results were published this week in the journal Kardiologia Polska.

Researchers from the Medical University of Silesia in Zabrze, Poland studied 155 patients who received an implantable cardioverter defibrillator (ICD) for secondary prevention of SCD.  Patients underwent MTWA testing using Cambridge Heart’s analytic spectral method prior to implantation, and were followed for major arrhythmic cardiac events (MACE) including SCD or intractable life-threatening arrhythmias requiring ablation or heart transplant.

At a median follow-up time of 22 months, patients with an abnormal MTWA test were 11 times more likely to experience a major arrhythmic cardiac event than patients with a normal MTWA result. The negative predictive value was 98.6 percent, indicating that patients with a normal or negative MTWA test are at very low risk of experiencing life-threatening arrhythmias.

For more information: www.cambridgeheart.com